← Every firm
Esperion FDA Recalls
2 recalls on file across drugs, 0 of them Class I and 0 still open. This firm is not matched to a listed company.
Newest first
Class I is the FDA's most serious grade: a reasonable probability of serious harm or death.
| Product |
|---|
| NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion TherClass IIIMar 27, 2024Failed dissolution specifications: out-of-specification bemp |
| Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Class IIIAug 16, 2023Failed dissolution specifications: below specification resul |